Houston medical device startup names new CEO

now at the helm

Houston-based Saranas has tapped a new leader amidst push to commercialize bleed detection technology. Photo via LinkedIn

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

Here are three of the latest updates on new execs and advisory appointments from Houston startups. Photo via Getty Images

3 Houston startups announce strategic appointments across health tech, materials, and software

short stories

Three Houston tech startups have new hires they're excited about this summer. From new board members to c-level execs, here's who's moving and shaking in Houston innovation.

Former Memorial Hermann CEO joins board of ZIBRIO

This Houston medical device startup has added a big name to its board. Photo courtesy of ZIBRIO

Dan Wolterman, who served as president and CEO of Memorial Hermann Health System for 15 years, has been named to the board of directors of Houston-based ZIBRIO. The health tech company, which was founded based on NASA technology, has developed a device that measures balance.

"We're delighted to have Dan on the team," says Katharine Forth, ZIBRIO CEO and co-founder, in a news release. "He understands ZIBRIO's vision to work across the full continuum of care, empowering older patients and clinicians with quantifiable fall prevention. His experience and enthusiasm will be invaluable in helping us to achieve it."

Falling is the top cause of trauma injury and trauma death across all age groups, according to ZIBRIO's release, and the current cost of falls in people over 65 is $50 billion – which is expected to double.

"ZIBRIO is coming to market at a time when population health and prevention are key for Healthcare systems to generate outcomes. They have a strong team and an elegant solution to a complex problem that will help millions," Wolterman says in the release.

Inhance adds to its C-suite

Inhance Technologies has added an integral member to its leadership. Photo via inhancetechnologies.com

Inhance Technologies, an international provider of polymer material science solutions based in Houston, has named its new CFO. Andrew Leeser, previously at Cimarron Energy, has joined the company to lead global finance, accounting and treasury functions, as well as human resources and information technology.

"I'm delighted to welcome Andrew to the Inhance Technologies family. He has an excellent track record in organizations spanning a range of industries, and I'm sure that his experience will help us continue on our upward trajectory," says Andrew Thompson, president and CEO of Inhance Technologies, in a news release. "We look forward to working with him to build a bright future for the company and our customers as we help them make a conscious choice towards more sustainable plastics."

The company just recently announced its expansion, including another new C-level exec and a new 75,000-square-foot site in St. Louis.

"I'm very pleased to have joined Inhance Technologies and I look forward to helping the organization achieve its goals over the next few years. With the significant growth in demand for our fully recyclable barrier technology Enkaseä, as well as our global expansion, there is no doubt I'm joining the company at an exciting time," says Leeser in the release.

Houston fintech unicorn names new council

Meet the new council dedicated to supporting HighRadius's new platform. Photo via LinkedIn

HighRadius, a Houston-based fintech company that reached unicorn status last year, has announced the members of its advisory council for its new microlearning and community platform Highako Academy.

Bob Shultz, managing partner of Quote-to-Cash Consulting, will serve as chairman of the council.

Other council members include:

  • John LaRocca, Sr. Director of Global Credit, Hitachi Vantara
  • Roger Torneden, Director of Business, Management and Legal Programs for UCLA Extension
  • R. Britt Hastey, Chair, Business Administration Department, Los Angeles City College
  • Bruce Lynn, Managing Partner, the FENG LLC
  • Scott Blakeley, Partner, Blakeley LLP

The council "will identify and improve courseware, certification programs and the methods of delivery based on current and future industry and professional trends," according to an email from the company. Highako Academy is aimed at helping teams and customers develop critical industry skills.

"Our customers have asked us for an online self-service learning platform, and that led us to launch highako.com as a beta platform last year," says Urvish Vashi of HighRadius in a recent release. "With 10,000+ users on the platform and a vibrant partner ecosystem consisting of credit groups, collection agencies, attorneys and industry associations, we see this echoing a larger trend of millennials and Gen Z gravitating towards microlearning platforms."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.

View All Listings